|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 317.00 EUR | +0.63% |
|
-2.76% | +0.16% |
| Apr. 16 | VIRBAC : Decent Q1; Clarity on US tariff exposure was a key takeaway |  |
| Apr. 16 | VIRBAC : Stifel still buying after Q1 results | CF |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Veterinary Drugs
| Capi. | Sales growth | Profitability (Composite) | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
| 3.06B | ||||||
| 73.18B | ||||||
| 6.95B | - | |||||
| 3.6B | ||||||
| 2.23B | ||||||
| 1.28B |
- Stock Market
- Equities
- VIRP Stock
- Charts Virbac
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
